S&P 500   4,595.04 (-1.29%)
DOW   34,656.96 (-1.36%)
QQQ   395.00 (-1.17%)
AAPL   164.28 (+2.52%)
MSFT   332.34 (-1.27%)
FB   327.82 (-3.02%)
GOOGL   2,856.00 (-1.88%)
AMZN   3,516.36 (-1.27%)
TSLA   1,137.66 (+0.06%)
NVDA   324.88 (-2.66%)
BABA   127.76 (-2.93%)
NIO   39.26 (-2.97%)
CGC   10.54 (-4.70%)
AMD   157.79 (-2.54%)
GE   95.64 (-2.80%)
MU   85.19 (-1.10%)
T   22.82 (-4.48%)
F   19.30 (-1.88%)
DIS   144.33 (-2.35%)
ACB   6.29 (-2.33%)
AMC   34.34 (-6.79%)
PFE   53.95 (+2.96%)
BA   196.42 (-1.05%)
S&P 500   4,595.04 (-1.29%)
DOW   34,656.96 (-1.36%)
QQQ   395.00 (-1.17%)
AAPL   164.28 (+2.52%)
MSFT   332.34 (-1.27%)
FB   327.82 (-3.02%)
GOOGL   2,856.00 (-1.88%)
AMZN   3,516.36 (-1.27%)
TSLA   1,137.66 (+0.06%)
NVDA   324.88 (-2.66%)
BABA   127.76 (-2.93%)
NIO   39.26 (-2.97%)
CGC   10.54 (-4.70%)
AMD   157.79 (-2.54%)
GE   95.64 (-2.80%)
MU   85.19 (-1.10%)
T   22.82 (-4.48%)
F   19.30 (-1.88%)
DIS   144.33 (-2.35%)
ACB   6.29 (-2.33%)
AMC   34.34 (-6.79%)
PFE   53.95 (+2.96%)
BA   196.42 (-1.05%)
S&P 500   4,595.04 (-1.29%)
DOW   34,656.96 (-1.36%)
QQQ   395.00 (-1.17%)
AAPL   164.28 (+2.52%)
MSFT   332.34 (-1.27%)
FB   327.82 (-3.02%)
GOOGL   2,856.00 (-1.88%)
AMZN   3,516.36 (-1.27%)
TSLA   1,137.66 (+0.06%)
NVDA   324.88 (-2.66%)
BABA   127.76 (-2.93%)
NIO   39.26 (-2.97%)
CGC   10.54 (-4.70%)
AMD   157.79 (-2.54%)
GE   95.64 (-2.80%)
MU   85.19 (-1.10%)
T   22.82 (-4.48%)
F   19.30 (-1.88%)
DIS   144.33 (-2.35%)
ACB   6.29 (-2.33%)
AMC   34.34 (-6.79%)
PFE   53.95 (+2.96%)
BA   196.42 (-1.05%)
S&P 500   4,595.04 (-1.29%)
DOW   34,656.96 (-1.36%)
QQQ   395.00 (-1.17%)
AAPL   164.28 (+2.52%)
MSFT   332.34 (-1.27%)
FB   327.82 (-3.02%)
GOOGL   2,856.00 (-1.88%)
AMZN   3,516.36 (-1.27%)
TSLA   1,137.66 (+0.06%)
NVDA   324.88 (-2.66%)
BABA   127.76 (-2.93%)
NIO   39.26 (-2.97%)
CGC   10.54 (-4.70%)
AMD   157.79 (-2.54%)
GE   95.64 (-2.80%)
MU   85.19 (-1.10%)
T   22.82 (-4.48%)
F   19.30 (-1.88%)
DIS   144.33 (-2.35%)
ACB   6.29 (-2.33%)
AMC   34.34 (-6.79%)
PFE   53.95 (+2.96%)
BA   196.42 (-1.05%)
NASDAQ:CNTG

Centogene Stock Competitors

$6.91
-0.23 (-3.22%)
(As of 11/30/2021 02:06 PM ET)
Add
Compare
Today's Range
$6.82
$7.30
50-Day Range
$6.91
$11.01
52-Week Range
$6.76
$14.00
Volume
914 shs
Average Volume
31,194 shs
Market Capitalization
$137.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-2.11

Centogene (NASDAQ:CNTG) Vs. PROG, VRDN, SERA, CELC, XGN, ENZ, BIOC, OPGN, VYNT, and PMD

Should you be buying Centogene stock or one of its competitors? The main competitors of Centogene include Progenity (PROG), Viridian Therapeutics (VRDN), Sera Prognostics (SERA), Celcuity (CELC), Exagen (XGN), Enzo Biochem (ENZ), Biocept (BIOC), OpGen (OPGN), Vyant Bio (VYNT), and Psychemedics (PMD). These companies are all part of the "medical laboratories" industry.

Centogene vs.

Viridian Therapeutics (NASDAQ:VRDN) and Centogene (NASDAQ:CNTG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, community ranking, risk, profitability, valuation and earnings.

Viridian Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Centogene has a beta of -2.11, meaning that its share price is 311% less volatile than the S&P 500.

12.6% of Centogene shares are held by institutional investors. 8.7% of Viridian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Centogene had 8 more articles in the media than Viridian Therapeutics. MarketBeat recorded 11 mentions for Centogene and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.82 beat Centogene's score of 0.02 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viridian Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Centogene
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Centogene has a net margin of -14.29% compared to Viridian Therapeutics' net margin of -5,037.78%. Viridian Therapeutics' return on equity of 0.00% beat Centogene's return on equity.

Company Net Margins Return on Equity Return on Assets
Viridian Therapeutics -5,037.78% N/A -48.09%
Centogene -14.29% -56.32% -24.54%

Centogene has higher revenue and earnings than Viridian Therapeutics. Centogene is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian Therapeutics$1.05 million385.62-$110.71 million-$29.44-0.63
Centogene$146.64 millionN/A-$24.49 million-$1.59-4.35

Centogene received 30 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave Centogene an outperform vote while only 54.55% of users gave Viridian Therapeutics an outperform vote.

CompanyUnderperformOutperform
Viridian TherapeuticsOutperform Votes
6
54.55%
Underperform Votes
5
45.45%
CentogeneOutperform Votes
36
66.67%
Underperform Votes
18
33.33%

Viridian Therapeutics currently has a consensus price target of $35.20, suggesting a potential upside of 88.84%. Centogene has a consensus price target of $18.75, suggesting a potential upside of 170.95%. Given Centogene's higher possible upside, analysts clearly believe Centogene is more favorable than Viridian Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viridian Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Centogene
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Centogene beats Viridian Therapeutics on 10 of the 16 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Centogene (NASDAQ:CNTG) vs. Its Competitors

TypeCentogeneMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$137.24M$2.60B$4.94B$7.86B
Dividend YieldN/A1.83%2.04%2.48%
P/E Ratio-4.357.6919.3921.34
Price / SalesN/A44.722,542.81281.32
Price / CashN/A10.3741.41137.68
Price / Book1.835.479.5410.62
Net Income-$24.49M$36.90M$95.31M$153.87M
7 Day Performance-24.73%-3.08%111.29%-3.20%
1 Month Performance-24.32%-12.51%106.84%-6.44%
1 Year Performance-44.90%1.47%161.16%29.76%

Centogene Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PROG
Progenity
2.1948 of 5 stars
$3.19
-2.2%
$4.00
-25.4%
-20.0%$522.36M$74.31M-0.84642Short Interest ↓
Gap Down
VRDN
Viridian Therapeutics
1.8782 of 5 stars
$18.64
-3.6%
$37.00
-98.5%
N/A$404.90M$1.05M-0.6327
SERA
Sera Prognostics
1.7 of 5 stars
$10.11
-3.0%
$18.50
-83.0%
N/A$296.16MN/A0.002,021Gap Up
CELC
Celcuity
2.2464 of 5 stars
$14.44
-0.4%
$40.40
-179.8%
+46.6%$215.30MN/A-7.1530
XGN
Exagen
2.6448 of 5 stars
$10.42
-2.5%
$25.25
-142.3%
-27.6%$168.43M$41.97M-6.72182Short Interest ↓
Gap Down
ENZ
Enzo Biochem
1.2131 of 5 stars
$3.35
-0.0%
N/A+65.0%$162.37M$117.73M19.71428News Coverage
Gap Up
BIOC
Biocept
1.7048 of 5 stars
$3.86
-0.8%
$20.00
-418.1%
-12.4%$65.00M$27.46M17.55107
OPGN
OpGen
2.0381 of 5 stars
$1.56
-1.3%
$5.50
-252.6%
-23.8%$60.76M$4.21M-1.31102Gap Up
VYNT
Vyant Bio
2.2 of 5 stars
$1.90
-3.2%
$5.00
-163.2%
-19.7%$55.08M$5.75M0.0040
PMD
Psychemedics
1.3198 of 5 stars
$8.12
-3.2%
N/A+91.1%$45.00M$21.36M-30.07138Short Interest ↓
ANPC
AnPac Bio-Medical Science
1 of 5 stars
$1.65
-1.8%
N/A-72.9%$25.28M$3.14M0.002,020Short Interest ↓
Gap Down
AMS
American Shared Hospital Services
0.4583 of 5 stars
$2.60
-4.6%
N/A+29.5%$15.26M$17.84M-2.5721News Coverage
This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.